Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
As leaders in cancer research, physician-scientists from Dana-Farber Cancer Institute showcased their advances at the Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC, April 1–5.
The AACR Annual Meeting highlights some of the best cancer science and medicine from institutions all over the world. Attendees stretch their boundaries, form collaborations, and discover exciting new concepts, tools, and techniques applicable to their own research.
This year's Program Committee Chair was Dana-Farber's Kornelia Polyak, MD, PhD, whose own primary area of research is the molecular basis of breast tumor evolution.
Visitors to Dana-Farber's booth connected with our physician-scientists – and learned more about our discoveries, innovations, and clinical trials.
Join the Twitter conversation at #aacr17
Follow us on LinkedIn
At this year's meeting, renowned Dana-Farber faculty shared discoveries, innovations, and insights:
Download this roster of select Dana-Farber conference speakers, with topics
Read about some of the abstracts we presented at the conference. Topics included:
Dana-Farber's Rizwan Haq, MD, PhD, wins Stand Up to Cancer award at AACRStand Up to Cancer (SU2C) announced at AACR that Dana-Farber physician Rizwan Haq, MD, PhD, has been awarded a $750,000 grant to identify and target mechanisms of resistance to immunotherapy.
Drug combination showing benefit in RAS-driven cancers reported at AACR in study by Dana-Farber scientists"Between one-quarter and one-third of patients got long-term clinical benefit," said Geoffrey Shapiro, MD, PhD, director of Dana-Farber's Early Drug Development Center.
Dana-Farber presents study showing some head and neck cancer patients benefit from continued checkpoint inhibitor treatment after tumor growthNew research, led by Robert Haddad, MD, suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug, according to investigators at Dana-Farber and other organizations.
Panagiotis Konstantinopoulos, MD, PhD, presents findings at AACR: drug combination boosts PARP inhibitor response in resistant ovarian cancerAbout one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumor when a kinase inhibitor was added to treatment. Panagiotis Konstantinopoulos, MD, PhD, presented the findings during an AACR clinical trials mini-symposium.
Judy Garber, MD, MPH, wins AACR award for outstanding clinical research achievementJudy E. Garber, MD, MPH, director of Dana-Farber's Center for Cancer Genetics and Prevention, has been honored by the AACR for outstanding achievement in clinical cancer research.
David Livingston, MD, wins major cancer research award from AACRDavid M. Livingston, MD, of Dana-Farber, has won a major award for discoveries in cancer research from AACR.
Search by last name:
Browse directory of